P019 OPTIMIZING NUTRITION RISK SCREENING AND FOLLOW-UP NUTRITION COUNSELING IN AN OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION

2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S54-S54
Author(s):  
Therezia AlChoufete ◽  
Siobhan Proksell ◽  
Marc Schwartz ◽  
Cassie Myers ◽  
Emily Weaver ◽  
...  

Abstract Background As management of Inflammatory Bowel Disease (IBD) advances, the outpatient (OP) population is shifting its fears from risks of malnutrition to those associated with over-nutrition and under-nutrition, lack of diet education, access to resources, mental health implications, and socioeconomic status. Failure to identify a patient at nutrition risk could lead to increased costs of care which can be avoided by proper nutrition screening and counseling with a Registered Dietitian (RD). The integration of nutrition counseling into the interdisciplinary care model for patients with IBD needs to be optimized to identify a broader range of risks to nutrition status in an efficient and objective format that can be applied universally in the OP IBD setting. Aims This study 1) explores a novel approach to nutrition risk screening within the OP IBD setting using an interdisciplinary team approach; and 2) evaluates correlations between an objective scoring method for biological and psychosocial risk with nutrition risk scores reported by an RD. Methods Two objective nutrition risk scoring methods were developed to capture biological (NUTR-OBJ) and lifestyle (NUTR-WELL) nutrition factors on a 0–6 scale (low-severe risk). Scores were determined using review of the electronic health record and a screening tool provided to patients. These scores were compared to the previously established IBD Biopsychosocial Complexity Grid, a tool which organizes this health information into biological and psychological domains and serves as the basis for algorithm-driven treatment plans within an IBD Medical Home. Results Data from 44 patients (mean age:35.2 years;47.7% female;56.8% Crohn’s Disease) were included in this study. BMI ranged from 18.08 to 37.92 kg/m2. BIO-C-PRO (mean=1.95,SD 1.86) and BIO-C-OBJ (mean 1.59, SD 1.76) indicate mild overall disease risk within our sample. NUTR-OBJ scores (mean=2.39, SD 1.28) showed no significant correlations with biological (BIO-C-PRO/OBJ) or psychosocial (PSY-C/H;SOC-SES;MI-C) scores. NUTR-WELL (mean=1.98,SD 1.36) showed strong positive correlations with PSY-C (r=.326, p<.05), PSY-H (r=.386,p<.01), SOC-SES (r=.306,p<.05), and MI-C (r=.473,p<.01). Discussion This study indicates a significant correlation between NUTR-WELL scores and psychosocial scores, suggesting validity for this nutrition screening tool to determine behaviors that may increase nutrition risk. Poor correlations between NUTR-OBJ and biological scores suggests that the need for nutrition intervention may not always be indicated by disease severity. This scoring system can potentially serve as a guide to maximize efficiency of follow-up appointments with an RD and avoid complications of care related to poor nutrition status that may be unidentified by disease risk alone. Further research is needed to confirm findings and extend to a larger sample.

2019 ◽  
Vol 14 (6) ◽  
pp. 773-777
Author(s):  
Mariëlle Roskam ◽  
Tim de Meij ◽  
Reinoud Gemke ◽  
Roel Bakx

Abstract Aims The aim of this study is to search for an association between infantile perianal abscesses and [development of] Crohn’s disease in a surgical population of children. Methods Patients who were surgically treated in the Amsterdam UMC between January 2000 and December 2014 were included in this retrospective cohort study. Data collected include: sex, date of birth, underlying conditions, age of onset, additional symptoms, pus cultures, endoscopic examination, histological examination, magnetic resonance imaging, faecal calprotectin levels, antibiotic treatment, surgical treatment strategy, and number of recurrences. Follow-up data were gathered from medical records and by contacting the patients and/or parents or the general practitioner. Results The study consisted of 62 patients of whom 60 were boys. Median age was 5 months [range 0–17 months]; 92% were under 1 year of age at diagnosis. A minority of patients had accompanying symptoms. In total, 72 abscesses were treated, 19 fistulas and 23 abscesses with fistula-in-ano. Follow-up data of 46 patients [74%] were available; none of the patients developed Crohn’s disease. Conclusions We found no association between isolated perianal abscesses as presenting symptom in early childhood and [development of] Crohn's disease. In young infants with isolated perianal disease, risk for inflammatory bowel disease seems low. In this specific population there seems no place for routine performance of endoscopic investigations. One should always take the risk of very-early-onset inflammatory bowel disease into account. Further research with a larger cohort of children and a longer follow-up time is required.


2010 ◽  
Vol 69 (OCE7) ◽  
Author(s):  
D. R. Owens ◽  
A. E. Wiskin ◽  
V. R. Cornelius ◽  
S. A. Wootton ◽  
R. M. Beattie

2020 ◽  
Vol 158 (3) ◽  
pp. S86-S87
Author(s):  
Therezia AlChoufete ◽  
Siobhan Proksell ◽  
Marc Schwartz ◽  
Cassie Myers ◽  
Emily Weaver ◽  
...  

2012 ◽  
Vol 25 (4) ◽  
pp. 319-322 ◽  
Author(s):  
A. E. Wiskin ◽  
D. R. Owens ◽  
V. R. Cornelius ◽  
S. A. Wootton ◽  
R. M. Beattie

Author(s):  
Roxana Mardare ◽  
Natasha Burgess ◽  
Dominic Studart ◽  
Protima Deb ◽  
Marco Gasparetto ◽  
...  

2021 ◽  
Vol 28 (1) ◽  
pp. e100337
Author(s):  
Vivek Ashok Rudrapatna ◽  
Benjamin Scott Glicksberg ◽  
Atul Janardhan Butte

ObjectivesElectronic health records (EHR) are receiving growing attention from regulators, biopharmaceuticals and payors as a potential source of real-world evidence. However, their suitability for the study of diseases with complex activity measures is unclear. We sought to evaluate the use of EHR data for estimating treatment effectiveness in inflammatory bowel disease (IBD), using tofacitinib as a use case.MethodsRecords from the University of California, San Francisco (6/2012 to 4/2019) were queried to identify tofacitinib-treated IBD patients. Disease activity variables at baseline and follow-up were manually abstracted according to a preregistered protocol. The proportion of patients meeting the endpoints of recent randomised trials in ulcerative colitis (UC) and Crohn’s disease (CD) was assessed.Results86 patients initiated tofacitinib. Baseline characteristics of the real-world and trial cohorts were similar, except for universal failure of tumour necrosis factor inhibitors in the former. 54% (UC) and 62% (CD) of patients had complete capture of disease activity at baseline (month −6 to 0), while only 32% (UC) and 69% (CD) of patients had complete follow-up data (month 2 to 8). Using data imputation, we estimated the proportion achieving the trial primary endpoints as being similar to the published estimates for both UC (16%, p value=0.5) and CD (38%, p-value=0.8).Discussion/ConclusionThis pilot study reproduced trial-based estimates of tofacitinib efficacy despite its use in a different cohort but revealed substantial missingness in routinely collected data. Future work is needed to strengthen EHR data and enable real-world evidence in complex diseases like IBD.


Sign in / Sign up

Export Citation Format

Share Document